PrE0905: Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)

Grants and Contracts Details

StatusActive
Effective start/end date2/27/2010/30/24

Funding

  • Alpha Oncology Incorporated: $107,675.00